Chronic Psychological Stress and the Regulation of Pro-Inflammatory Cytokines: A Glucocorticoid-Resistance Model

Gregory E. Miller  
Washington University

Sheldon Cohen  
Carnegie Mellon University

A. Kim Ritchey  
Children’s Hospital of Pittsburgh

This study examined whether chronic stress impairs the immune system’s capacity to respond to hormonal signals that terminate inflammation. Fifty healthy adults were studied; half were parents of cancer patients, and half were parents of healthy children. Parents of cancer patients reported more psychological distress than parents of healthy children. They also had flatter diurnal slopes of cortisol secretion, primarily because of reduced output during the morning hours. There was also evidence that chronic stress impaired the immune system’s response to anti-inflammatory signals: The capacity of a synthetic glucocorticoid hormone to suppress in vitro production of the pro-inflammatory cytokine interleukin-6 was diminished among parents of cancer patients. Findings suggest a novel pathway by which chronic stress might alter the course of inflammatory disease.

Key words: psychoneuroimmunology, chronic stress, cortisol, pro-inflammatory cytokines, cancer, social support

Psychological stress has been linked with a broad array of adverse health outcomes. Studies have demonstrated that stress heightens risk for upper respiratory infection (Cohen et al., 1998; Cohen, Tyrrell, & Smith, 1991; Sheridan & Dobbs, 1994), accelerates the progression of coronary artery disease (Kaplan et al., 1983; Rozanski, Blumenthal, & Kaplan, 1999), and exacerbates the course of autoimmune disorders (Grantham, 1993; Rabin, 1999; Whitacre, Cummings, & Griffin, 1995; Zautra, Burleson, Matt, & Roth, 1994). To elucidate the mechanisms responsible for these effects, researchers have explored the relationship between psychological stress and the immune system, the body’s chief defense against many diseases. Numerous links between stress and the immune response have been described. Studies have shown that stress is accompanied by suppressed lymphocyte proliferative responses, reduced control of latent herpes viruses, blunted humoral responses to immunization, and poorer wound healing (Cohen, Miller, & Rabin, 2001; Herbert & Cohen, 1993; Kiecolt-Glaser, Glaser, Gravenstein, Malarkey, & Sheridan, 1996; Kiecolt-Glaser, Marucha, Malarkey, & Glaser, 1999; Marucha, Kiecolt-Glaser, & Favagehi, 1998).

These findings have given rise to an immunosuppression model depicting relations between stress, immunity, and disease. The model’s basic tenet is that stress heightens risk for adverse health outcomes by suppressing the immune response in a fashion that leaves the host vulnerable to opportunistic disease. Although the exact pathways responsible for this effect have not yet been elucidated, stress is assumed to downregulate immunity by (a) activating autonomic nervous system fibers that descend from the brain to lymphoid organs (Felten & Felten, 1994), (b) triggering the secretion of hormones and neuropeptides that bind to white blood cells and alter their function (Blalock, 1994), and (c) inducing immunomodulatory coping behaviors, such as cigarette smoking and alcohol consumption (Kiecolt-Glaser & Glaser, 1988).

Under these conditions, the immune system’s capacity to mount an effective response to challenge is diminished (Andersen, Kiecolt-Glaser, & Glaser, 1994; Cohen & Williamson, 1991). The immunosuppression model makes important contributions to our understanding of stress-related disease. It is particularly
good at explaining how stress might increase susceptibility to negative health outcomes that arise because of compromised host resistance. Infectious disease, some forms of cancer, and wound healing all fall into this category. An important limitation of the immunosuppression model, however, is that it does not offer a parsimonious explanation for how stress might influence diseases whose central feature is excessive inflammation. This is the case in many disease contexts: Inflammation plays a role in the pathogenesis of allergic, autoimmune, rheumatologic, and cardiovascular diseases and contributes to the formation of illness symptoms in many infectious diseases. These conditions seem to be exacerbated by stressful experience (Cohen et al., 1991, 1998; Grant, 1993; Rozanski et al., 1999; Whitacre et al., 1995; Wright, Rodriguez, & Cohen, 1998; Zautra et al., 1994). However, it is difficult to see how the immunosuppression model could account for these findings. In fact, the most straightforward prediction that could be derived from it is that stress should improve disease course by suppressing the inflammatory response. The available data in humans generally do not bear out this prediction.1

So, how might the impact of stress on inflammatory conditions be explained? To answer this question, we propose a glucocorticoid-resistance model. Its basic premise is that chronic stress diminishes the immune system’s sensitivity to glucocorticoid hormones that normally terminate the inflammatory cascade. The model begins with the notion that chronic stress elicits secretion of the hormonal products of the hypothalamic–pituitary–adrenocortical (HPA) and sympathetic adrenal medullary (SAM) axes. With continued exposure to high concentrations of these hormones, white blood cells mount a counterregulatory response and downregulate the expression and/or function of receptors responsible for binding glucocorticoid hormones. This receptor downregulation subsequently diminishes the immune system’s capacity to respond to cortisol’s anti-inflammatory actions. To the extent that this process occurs, inflammatory processes flourish and the course of disease subsequently worsens.2

This model’s validity rests on a series of important assumptions. The first is that stressful circumstances can trigger ongoing secretion of hormones from the HPA and SAM axes. A number of studies have yielded support for this assumption, demonstrating that when environmental demands outstrip coping resources, the body’s output of cortisol, epinephrine, and norepinephrine increases (Baum & Grunberg, 1995; Kirschbaum & Hellhammer, 1989; Weiner, 1992). These hormonal increases, however, are not uniformly observed. In patients with posttraumatic stress disorder, for instance, epinephrine and norepinephrine are persistently elevated, but cortisol secretion is persistently blunted (Yehuda, 2000). A second assumption of the model is that cortisol plays a central role in regulating the inflammatory response to infection and injury. Support for this assumption comes from studies demonstrating that disruption of the HPA axis predisposes rodents to chronic inflammatory illness, which resolves once hormonal pathways have been restored through the administration of synthetic glucocorticoids (Chrousos, 1995; Sternberg, Hill, et al., 1989; Sternberg, Young, et al., 1989). The model’s final assumption is that with prolonged exposure to hormones, glucocorticoid receptors are downregulated and the immune system’s sensitivity to the cortisol declines. Evidence of this phenomenon derives from clinical studies of inflammatory disease that show that in a subset of patients, long-term administration of synthetic glucocorticoid med-

1 Although stress generally does not improve the course of inflammatory disease in humans, there is some evidence to suggest that symptoms of autoimmune disease may temporarily subside during extremely stressful circumstances (Nisipeanu & Korczyn, 1993; Potter & Zautra, 1997). Evidence of this phenomenon has also occasionally emerged in animal studies, both in rheumatoid arthritis (Rabin, 1999; Whitacre et al., 1995) and in infectious disease, where stress-related cortisol increases protected animals from the lethal consequences of respiratory inflammation (Sheridan et al., 1998).

2 By using the term glucocorticoid resistance here, we do not mean to imply that stress induces a clinical syndrome where the immune system becomes completely unresponsive to glucocorticoids. We are simply arguing that stress will, to some extent, diminish the immune system’s glucocorticoid sensitivity and, by doing so, will facilitate the continued expression of pro-inflammatory cytokines following infection and/or injury. In this sense, we are using the term in the same way that researchers in this field use immunosuppression—not to refer to a clinical entity but instead to a pattern of immune system changes that accompany chronic stress.
affective pathway that we examined was depression, as it has been linked with diminished glucocorticoid sensitivity in both nervous system and immune system tissues (A. H. Miller, Pariente, & Pearce, 1999; Gold, Goodwin, & Chrousos, 1988a, 1988b). The behavioral pathways we explored were health practices that have been linked with the immune response in previous research (Cohen, Doyle, Skoner, Rabin, & Gwaltney, 1997; Kiecolt-Glaser & Glaser, 1988; G. E. Miller, Cohen, & Herbert, 1999) and included smoking, alcohol consumption, physical activity, and sleep hygiene. To explore the contribution of hormonal pathways, we had parents collect saliva samples as they went about normal daily activities, and we used these samples to estimate diurnal patterns of cortisol secretion.

Social support can play a powerful role in buffering people from the biological consequences of stressful experience (Kamarck, Manuck, & Jennings, 1990; Kirschbaum, Klauer, Sigrun-Heide, & Hellhammer, 1995; Uchino, Cacioppo, & Kiecolt-Glaser, 1996). Only a handful of studies, however, have examined whether this effect extends to the immune system (Baron, Cutrona, Hicklin, Russell, & Lubaroff, 1990; Glaser et al., 1992; Glaser, Kiecolt-Glaser, Speicher, & Holliday, 1985; Kiecolt-Glaser, Dura, Speicher, Trask, & Glaser, 1991; Kiecolt-Glaser, Garner, et al., 1984; Kiecolt-Glaser, Speicher, Holliday, & Glaser, 1984). To address this issue, we assessed the extent to which parents felt they had two forms of social support available to them: appraisal support, or the sense that one has others he or she can talk to about problems, and tangible support, or the feeling that one has others who will provide material aid when it is needed.

The primary hypotheses of this study were that (a) chronic stress would diminish the capacity of dexamethasone to suppress the production of pro-inflammatory cytokines; (b) negative affective states, maladaptive health practices, and disrupted cortisol secretion patterns would contribute to this process; and (c) high levels of social support would buffer parents from any reductions in glucocorticoid sensitivity that might arise from the stress of caring for a child with cancer.

Method

Participants

Fifty adults participated in this study. Half of them were parents of children undergoing active treatment for cancer; the remaining half were parents of medically healthy children. The two groups were matched with respect to age, gender, ethnicity, and marital status. All parents were in excellent health, defined as having (a) no history of chronic illness involving the cardiovascular, endocrine, or immune systems and (b) no use of prescription medications within the previous 3 months, with the exception of oral contraceptives. None of the female participants had been pregnant or lactating within 12 months of entering the study.

The parents of children with cancer were recruited from the Hematology/Oncology Clinic at the Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania. To be eligible for the study, they had to be caring for a child undergoing active treatment for cancer who was 1–18 years old and living at home. Almost half of the parents were caring for a child with acute lymphoblastic leukemia (44%), the most common form of childhood cancer. The remainder were caring for a child with neuroblastoma (16%), hepatoblastoma (8%), Wilms’ tumor (4%), osteogenic sarcoma (4%), or other malignancies. The children had been diagnosed with cancer an average of 9.6 months prior to study entry ($SD = 9.5$, range = 1–35 months). In most cases, this diagnosis was for a primary tumor (76%), although in some cases, it was for a recurrence (24%). All children were undergoing chemotherapy at the time their parents entered the study. Additional treatment modalities included radiation therapy (60%), surgery (40%), and bone marrow transplantation (20%). To estimate disease severity, we asked each child’s attending physician to rate his or her prognosis on scale ranging from 1 (very poor) to 5 (very good). The mean rating was 2.8 ($SD = 1.4$), indicating an average prognosis, although scores were almost equally distributed across the scale.

The parents of medically healthy children were recruited through advertisements in local media. To be eligible for the study, they had to (a) have at least one child aged 1–18 years living at home; (b) match a parent in the cancer group on age, gender, ethnicity, and marital status; (c) have children with a lifetime history free of chronic medical and psychiatric illness; and (d) be free of major stressors, such as divorce, bereavement, unemployment, and family illness during the past year. These eligibility requirements ensured that parents of medically healthy children were experiencing relatively low levels of psychological stress.

Procedures

All parents attended an initial laboratory session. After providing written informed consent, they completed a short battery of psychosocial instruments (described below). Parents were then seated in a comfortable chair and had 35 ml of blood drawn through antecubital venipuncture. The blood was drawn into heparin-coated Vacutainers (Becton-Dickinson, Franklin Lakes, NJ) and was immediately delivered to the laboratory, where assays began within 2 hr. To control for diurnal variations in immune response, we performed all blood draws between 9:00 a.m. and 12:00 p.m.

Over the course of the next 2 days, parents gathered salivary cortisol samples as they went about their normal daily activities. To facilitate this process, we lent them programmable wristwatches (WatchMinder, Irvine, CA) that generated audible beeps five times each day. The beeps cued parents to begin a standard saliva collection protocol that involves chewing on a cotton dental roll (Salivette, Sarstedt Inc., Newton, NC) until it is saturated with saliva. The dental roll is then sealed in a plastic centrifuge tube and refrigerated until it is returned to the laboratory (Kirschbaum & Hellhammer, 1989).

The watches signaled parents to collect saliva 1, 4, 9, 11, and 13 hr after waking in the morning. Validation studies have shown that this collection schedule yields a fairly robust estimate of total daily cortisol secretion (MacArthur Foundation Network on SES and Health, 2000). To ensure compliance with the schedule, a unique code word appeared on the wristwatch display each time the alarm sounded and disappeared approximately 5 min later. Parents were instructed to copy the code word onto saliva collection containers. Samples with missing or incorrect codes were excluded from analyses. Consistent with previous studies (Ockenfels et al., 1995), approximately 18% of participants’ saliva samples (93/500) were excluded from analyses because they had missing or incorrect codes, were not collected properly, or were not collected at all.

Measuring Psychological States

Perceived stress. We assessed parents’ levels of perceived psychological stress with the 10-item Perceived Stress Scale (PSS; Cohen & Wills, 1988). This measure taps the extent to which people find their lives to be unpredictable, uncontrollable, and unmanageable. It covers the previous 1 month. The PSS showed high levels of internal consistency in this sample ($\alpha = .92$).

Mood states. We assessed mood states using 25 adjectives derived predominately from the Profile of Mood States (McNair, Lorr, & Droppelman, 1971; Urasa & Hertzog, 1989). These items were combined to form composites reflecting negative affect ($\alpha = .80$) and positive affect ($\alpha = .91$) during the previous 1 month.

Depressive symptoms. We assessed parents’ depressive symptoms with the Center for Epidemiologic Studies—Depression Scale (Radloff,
Measuring Health Practices

We measured health practices using a self-report battery used in our previous work (G. E. Miller et al., 1999; G. E. Miller, Cohen, Rabin, Skoner, & Doyle, 1999). Participants were classified as smokers if they reported daily use of cigarettes, pipes, or cigars. Alcohol use was determined by counting the number of alcoholic drinks consumed during a typical week. A drink was considered a bottle or can of beer, a glass of wine, or a shot of hard liquor. Regular physical activity was measured with a modified version of the Paffenbarger Activity Scale (Paffenbarger, Blair, Lee, & Hyde, 1993). This scale provided estimates of typical weekly energy expenditure and the number of minutes of brisk physical activity per week. Sleep hygiene was assessed with the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). This scale yields estimates of subjective sleep quality (on a 1–4 scale, with higher numbers indicating better sleep quality) and sleep efficiency (the percentage of time in bed actually spent sleeping).

This battery of measures has excellent psychometric properties. Test–retest reliability coefficients, assessed over a 6-month period, exceed .70 for all items except subjective sleep quality (G. E. Miller, Cohen, & Herbert, 1999). With regard to validity, our work with this inventory has shown that clinically depressed patients report greater tobacco use, lower physical activity, and poorer sleep hygiene compared with healthy controls. These health practices also have been linked with in vitro measures of immune response, including reduced natural killer cell cytotoxicity and poorer mitogen-stimulated lymphocyte proliferation (G. E. Miller, Cohen, & Herbert, 1999; G. E. Miller, Cohen, Rabin, et al., 1999) as well as impaired host resistance to upper respiratory infection (Cohen et al., 1997).

Measuring Daily Patterns of Cortisol Secretion

After they were returned to the laboratory, salivettes were centrifuged for 5 min at 3,000 rpm until a clear, low-viscosity supernatant emerged. The supernatants were then collected and frozen at −20 °C until the end of the study, at which time they were shipped on dry ice to the Institute of Experimental Psychology II at the University of Düsseldorf, Düsseldorf, Germany. Cortisol assays were performed in duplicate using a time-resolved fluorescence immunoassay with a cortisol-biotin conjugate as a tracer (Kirschbaum, Kudielka, Gaab, Schommer, & Hellhammer, 1999; Puessner, Hellhammer, & Kirschbaum, 1999). This assay has a sensitivity of 0.43 nmol/L. The intra-assay coefficient of variation (CV) was less than 10%. The interassay CV was less than 12%.

After cortisol values had been log-transformed, each day’s data were used to create two indices of secretion for later analysis. The first index was an area-under-the-curve measure reflecting the total volume of cortisol secretion over the day. This was computed using the trapezoidal method, such that higher values reflect greater cortisol release. The second index was a slope reflecting the diurnal pattern of cortisol secretion. This was created by estimating a simple linear regression model for each participant, where his or her cortisol values were regressed on time since waking. Because cortisol secretion generally declines over the day, most healthy individuals have negatively signed diurnal slopes. As a result, lower values, reflecting more rapid declines, are viewed as adaptive. In contrast, higher slope values, as they approach zero, reflect flat diurnal rhythms and are viewed as evidence of HPA dysregulation (McEwen, 1998; Stone et al., 2001; Yehuda, Teicher, Trestman, Levengood, & Siever, 1996). In a very small minority of cases (3 parents of cancer patients and 1 parent of a medically healthy child), we observed a daily slope value that exceeded zero, indicating abnormally timed diurnal cortisol surges and/or increasing levels over the day.

To obtain more reliable indices of cortisol secretion, we averaged values derived from the 2 days of ambulatory data collection. The correlation between area-under-the-curve values from the 2 days was r = .39, and the correlation between slope values was r = .22. Similarly, modest day-to-day stability has been seen in other studies in this area (Ockenfelds et al., 1995; Smyth et al., 1997).

Measuring Immune System Glucocorticoid Sensitivity

To measure glucocorticoid sensitivity, we incubated 1.8 ml of whole blood with 200 μl of dexamethasone phosphate dissolved in phosphate buffering solution for 30 min. The final in–well concentrations of dexamethasone were 0 nM, 10 nM, 100 nM, and 250 nM for assays involving IL-1β and TNF-α, and 0 nM, 10 nM, 50 nM, and 100 nM for assays involving IL-6. We then added 220 μl of lipopolysaccharide (LPS) dissolved in phosphate buffering solution to each sample. The final concentration of LPS was 100 ng/ml for assays involving IL-1β and TNF-α and 3 ng/ml for assays involving IL-6. The samples were then transferred to 24-well plates and incubated overnight (16–18 hr) at 37 °C with 5% CO₂.

The plates were removed from the incubator and immediately centrifuged for 10 min at 2,000 rpm. Plasma samples were then aspirated and stored at −20 °C until the end of the study. At that time, samples were thawed and cytokine assays were performed in duplicate in a single batch using commercially available ELISA kits (R&D Systems, Minneapolis, MN). Assay sensitivity was 4 pg/ml for IL-1β, 3 pg/ml for IL-6, and 16 pg/ml for TNF-α. The intra- and interassay coefficients of variation were less than 9% for all cytokine assays. This is a modified version of a protocol that has been used to examine whether acute bouts of exercise modulate glucocorticoid sensitivity (DeRijk et al., 1996; Smits, Grunberg, Derijk, Sterk, & Hiemstra, 1998).

Results

Preliminary Analyses

Table 1 displays characteristics of the sample. Parents of cancer patients did not differ from parents of medically healthy children with respect to age, gender, ethnicity, marital status, years of education, height, weight, body mass index, over-the-counter medication use, or oral contraceptive use (all ps > .20). The groups did differ with respect to family size, however, with parents of cancer patients having marginally more children living at home (t(48) = 1.92, p < .07). Statistically controlling for family size, however, did not substantively alter any of the findings we report in the remainder of this article.

Psychological Outcomes

Table 2 presents psychological outcomes for the groups. Parents of cancer patients reported significantly more psychological dis-
tress than parents of medically healthy children. They described higher levels of perceived stress, \( t(48) = 2.03, p < .05 \); greater overall negative affect, \( t(48) = 2.38, p < .03 \); less overall positive affect, \( t(48) = -3.04, p < .01 \); and significantly more frequent depressive symptoms, \( t(48) = 3.44, p < .01 \).

### Baseline Cytokine Production

We next examined whether chronic stress influenced the extent of parents’ baseline cytokine production. In the LPS-stimulated cultures treated with saline (but not dexamethasone), parents of cancer patients exhibited lower average levels of IL-6, greater average levels of TNF-\( \alpha \), and no differences in IL-1\( \beta \), compared with parents of healthy children. None of these differences, however, approached statistical significance \((p > .13)\). The \( \bar{M} \pm SD \) values for parents of cancer patients were \( 733 \pm 820, 1,110 \pm 881, \) and \( 1,358 \pm 1,001 \) for IL-6, TNF-\( \alpha \), and IL-1\( \beta \), respectively. The corresponding values for parents of medically healthy children were \( 1,134 \pm 783, 800 \pm 407, \) and \( 1,305 \pm 672 \).

### Immune System Glucocorticoid Sensitivity

We next explored whether chronic stress influenced the immune system’s sensitivity to the anti-inflammatory actions of glucocorticoids. This was done using a series of repeated-measures analyses of variance, with group (parents of cancer patients vs. parents of healthy children) and dosage (low vs. medium vs. high dexamethasone concentration) serving as the independent variables. To control for variability in the extent of baseline cytokine production, we included in these analyses cytokine values from the saline-treated cultures as covariates. Average values for each cytokine appear in Table 3.

#### IL-1\( \beta \)

There were no reliable differences in dexamethasone’s capacity to suppress IL-1\( \beta \) production between parents of cancer patients and parents of medically healthy children, \( F(1, 35) = 1.08, p > .31 \). A significant main effect of dosage emerged, however, indicating that IL-1\( \beta \) production declined with greater concentrations of dexamethasone, \( F(2, 34) = 159.68, p < .01 \). The Group \( \times \) Dosage interaction was nonsignificant, \( F(2, 34) = 1.24, p > .29 \). These findings are illustrated in Figure 1.

#### IL-6

Parents of cancer patients showed significantly less dexamethasone suppression of IL-6 production compared with parents of medically healthy children, \( F(1, 40) = 4.12, p < .05 \). This pattern of findings was consistent across dosages of dexamethasone as indicated by the nonsignificant Group \( \times \) Dosage interaction, \( F(2, 39) = 2.45, p > .10 \). A main effect of dosage emerged in this analysis, with IL-6 production declining with higher concentrations of dexamethasone, \( F(2, 39) = 88.54, p < .01 \). These results are illustrated in Figure 2.

#### TNF-\( \alpha \)

There were no significant differences in dexamethasone-related suppression of TNF-\( \alpha \) production between parents of cancer patients and parents of medically healthy children, \( F(1, 45) = 0.01, p > .95 \). There was also no significant Group \( \times \) Dosage interaction, \( F(2, 44) = 0.71, p > .49 \). A reliable main effect of dosage was found, with TNF-\( \alpha \) production declining in the presence of greater concentrations of dexamethasone, \( F(2, 44) = 439.92, p < .01 \). These findings are illustrated in Figure 3.

### Depression, Health Practices, and Cortisol as Mediators

Next, we examined whether depressive symptoms, health practices, or cortisol secretion might operate as pathways linking chronic stress with declines in IL-6 glucocorticoid sensitivity. Standard procedures require that data meet three criteria to provide

---

**Table 1**

**Demographic Characteristics of the Sample**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Parents of children with cancer</th>
<th>Parents of medically healthy children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>( M = 36.5 \pm 6.0 ) Range 24–47</td>
<td>( M = 37.5 \pm 5.5 ) Range 28–47</td>
</tr>
<tr>
<td>% female</td>
<td>( 76.0 )</td>
<td>( 76.0 )</td>
</tr>
<tr>
<td>% Caucasian</td>
<td>( 88.0 )</td>
<td>( 88.0 )</td>
</tr>
<tr>
<td>% married</td>
<td>( 80.0 )</td>
<td>( 80.0 )</td>
</tr>
<tr>
<td>No. of children living at home</td>
<td>( 2.5 \pm 1.3 ) Range 1–6</td>
<td>( 1.9 \pm 1.1 ) Range 1–6</td>
</tr>
<tr>
<td>Education (years)</td>
<td>( 15.2 \pm 2.7 ) Range 9–20</td>
<td>( 15.5 \pm 2.2 ) Range 12–18</td>
</tr>
<tr>
<td>Height (m)</td>
<td>( 1.7 \pm 0.1 ) Range 1.6–1.9</td>
<td>( 1.7 \pm 0.0 ) Range 1.5–1.9</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>( 78.2 \pm 28.1 ) Range 49–172</td>
<td>( 70.2 \pm 15.2 ) Range 51–104</td>
</tr>
<tr>
<td>Body mass index (kg/m(^2))</td>
<td>( 27.0 \pm 7.5 ) Range 17–46</td>
<td>( 24.7 \pm 5.2 ) Range 19–40</td>
</tr>
<tr>
<td>Using OTC medications</td>
<td>( 48.0 )</td>
<td>( 56.0 )</td>
</tr>
<tr>
<td>Using oral contraceptives</td>
<td>( 20.0 )</td>
<td>( 32.0 )</td>
</tr>
</tbody>
</table>

**Note.** \( n = 25 \) in each group. OTC = over the counter.

**Table 2**

**Perceived Stress, Mood States, and Depressive Symptoms**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Parents of children with cancer</th>
<th>Parents of medically healthy children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perceived stress</td>
<td>( 18.3 \pm 8.2 )</td>
<td>( 13.8 \pm 7.6 )</td>
</tr>
<tr>
<td>Negative affect</td>
<td>( 25.6 \pm 9.8 )</td>
<td>( 19.6 \pm 7.7 )</td>
</tr>
<tr>
<td>Positive affect</td>
<td>( 19.3 \pm 5.5 )</td>
<td>( 23.7 \pm 4.7 )</td>
</tr>
<tr>
<td>Depressive symptoms</td>
<td>( 16.8 \pm 12.6 )</td>
<td>( 7.2 \pm 6.0 )</td>
</tr>
</tbody>
</table>

**Note.** \( n = 25 \) in each group. For each construct, means with different subscripts indicate group differences at \( p < .05 \) by independent samples \( t \) test.
and statistically controlling for them did not appreciably reduce cytokine production. SEM/H11005
vitro interleukin-1/H9252
related to glucocorticoid sensitivity,
of medically healthy children. Depressive symptoms were unre-
earlier, described more frequent depressive symptoms than parents
Figure 1. Chronic stress and dexamethasone’s capacity to suppress in vitro interleukin-1β (IL-1β) production. Values are adjusted for baseline cytokine production. SEM = standard error of the mean.

evidence consistent with a mediational hypothesis: (a) The predic-
tor variable (group membership) must be related to the outcome
variable (glucocorticoid sensitivity), (b) the predictor variable
must be related to the hypothesized mediator (variables represent-
ing depressive symptoms, health practices, and cortisol secretion),
and (c) the magnitude of the relationship between the predictor and
outcome variables must be substantially reduced when the medi-
ator is statistically controlled (Stone, 1992). At the outset we
should note that these methods cannot provide a strong test of
whether the mediators operate in a causal fashion. Such a test
would require an experimental manipulation. What they can pro-
provide, however, is an indication of whether each mechanism relates
to chronic stress and IL-6 glucocorticoid sensitivity in a way that
is consistent with a mediational hypothesis.

Depressive symptoms. Parents of cancer patients, as we noted
earlier, described more frequent depressive symptoms than parents
of medically healthy children. Depressive symptoms were unre-
related to glucocorticoid sensitivity, t(40) = -0.5, p > .76, however,
and statistically controlling for them did not appreciably reduce
group differences in IL-6 glucocorticoid sensitivity (< 2% reduc-
tion in variance accounted for by group). These findings suggest
that depressive symptoms were not responsible for the decline in
IL-6 glucocorticoid sensitivity among parents of cancer patients.4

Health practices. Table 4 presents health practices for the
sample. Parents of cancer patients reported significantly worse
sleep quality than parents of medically healthy children,
M/H11005 = 2.65, p < .02. They also reported marginally less efficient
sleep, t(48) = -1.76, p < .09. The two groups did not differ with
respect to smoking status, alcohol consumption, minutes per week
of brisk physical activity, or weekly energy expenditure (all ps > .18).
Statistically controlling for the two health practices that
differentiated the groups, sleep quality and sleep efficiency, did
not appreciably reduce disparities in IL-6 glucocorticoid sensitiv-
ity (< 5% reduction in total variance accounted for), nor did
controlling for the other health practices we assessed or height,
weight, body mass index, over-the-counter medication use, or oral
contraceptive use (< 5% reduction in variance accounted for by

Table 3
Mean Pro-Inflammatory Cytokine Values

<table>
<thead>
<tr>
<th>Cytokine and dexamethasone dosage</th>
<th>Parents of children with cancer</th>
<th>Parents of medically healthy children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M</td>
<td>SD</td>
</tr>
<tr>
<td>Interleukin-1β</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 nM dexamethasone</td>
<td>1,111</td>
<td>301</td>
</tr>
<tr>
<td>100 nM dexamethasone</td>
<td>317</td>
<td>127</td>
</tr>
<tr>
<td>250 nM dexamethasone</td>
<td>167</td>
<td>115</td>
</tr>
<tr>
<td>Interleukin-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 nM dexamethasone</td>
<td>1,036</td>
<td>291</td>
</tr>
<tr>
<td>100 nM dexamethasone</td>
<td>545</td>
<td>152</td>
</tr>
<tr>
<td>250 nM dexamethasone</td>
<td>351</td>
<td>165</td>
</tr>
<tr>
<td>Tumor necrosis factor-α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 nM dexamethasone</td>
<td>853</td>
<td>134</td>
</tr>
<tr>
<td>100 nM dexamethasone</td>
<td>535</td>
<td>106</td>
</tr>
<tr>
<td>250 nM dexamethasone</td>
<td>353</td>
<td>96</td>
</tr>
</tbody>
</table>

Note. Cytokine production following stimulation with lipopolysaccharide (100 ng/ml for assays involving interleukin-1β and tumor necrosis factor-α and 3 ng/ml for assays involving interleukin-6). Values are adjusted for baseline cytokine production, that is, in a culture in which no dexamethasone is added. All values are in picograms per milliliter.

4 These mediational analyses use aggregate IL-6 production as an outcome. In this index, values are collapsed across low, medium, and high doses of dexamethasone after baseline IL-6 production has been covaried out. The same strategy is used in the next section, in which we examine the buffering role of social support. Identical results emerge when analyses are computed separately for each dosage.
differ with respect to cortisol concentration at any other time of the day (ts < 0.50, ps > .62). No group differences emerged for the area-under-curve measure reflecting total daily volume of cortisol secretion (M = 10.61, SD = 1.62 vs. M = 11.08, SD = 1.93), t(44) = −1.10, p > .28.

Despite these findings, cortisol slopes were unrelated to glucocorticoid sensitivity, r(40) = −.05, p > .76, and statistically controlling for them did not appreciably reduce group differences in IL-6 glucocorticoid sensitivity (< 5% reduction in variance accounted for by group). The same was true of cortisol secretion at 1 hr postawakening, r(40) = −.20, p > .23 (< 5% reduction in total variance accounted for). These findings suggest that diurnal patterns of cortisol secretion were not responsible for the decline in IL-6 glucocorticoid sensitivity among parents of cancer patients.

Social Support as a Stress Buffer

To determine whether social support buffered parents of cancer patients from declines in IL-6 glucocorticoid sensitivity, we computed a series of multiple regression equations where sensitivity was predicted by group (parents of cancer patients vs. parents of medically healthy children), social support (either appraisal or tangible support scores), and a product term representing the interaction of these variables (Aiken & West, 1991). A significant interaction between group membership and tangible social support emerged (for interaction term, ∆R² = .01, b = .46; t(43) = 2.04, p < .05). Tangible social support was unrelated to glucocorticoid sensitivity among parents of medically healthy children (simple slope = .01). Among parents of cancer patients, however, glucocorticoid sensitivity declined (i.e., resistance increased) to the extent that parents reported low tangible support (simple slope = −.05). These findings suggest that tangible support buffered participants from the reduction in IL-6 glucocorticoid sensitivity that accompanies caring for a child with cancer. No evidence of a buffering effect was detected for appraisal support (for interactions term, p > .40). The parent groups did not differ with respect to mean levels of either tangible or appraisal support (ps > .25).

Discussion

This study’s primary hypothesis was that chronic psychological stress would impair the immune system’s capacity to respond to the anti-inflammatory actions of glucocorticoid hormones. It yielded preliminary support for this hypothesis. Among parents of cancer patients, dexamethasone’s capacity to suppress IL-6 production was significantly reduced compared with parents of medically healthy children. These findings are consistent with recent studies demonstrating that the immune system’s glucocorticoid sensitivity declines following short bouts of physical activity and acute stress in humans (DeRijk et al., 1996; Rohleder, Schommer, Hellhammer, Engel, & Kirschbaum, 2001; Smits et al., 1998) and following intermittent bouts of social disruption stress in mice (Avitsur, Stark, & Sheridan, 2001; Stark et al., 2001). Collectively, these findings suggest a novel mechanism through which psychological stress could influence the onset and/or progression of conditions that involve excessive inflammation. This is the case in many disease contexts, including allergic, autoimmune, cardiovascular, infectious, and rheumatologic illnesses. A stress-induced immunosuppression model, as we mentioned earlier, cannot provide a parsimonious explanation for how such a process might occur.

This study also explored pathways linking chronic stress with reductions in IL-6 glucocorticoid sensitivity. In terms of affective pathways, parents of cancer patients reported more frequent depressive symptoms than parents of healthy children, but subsequent analyses suggested that depression did not operate as a mediator. It is possible that chronic stress contributes to declines in immune system glucocorticoid sensitivity through other affective pathways (e.g., anxiety) or through nonaffective pathways, such as the formation of intrusive thoughts or feelings of helplessness. In terms of health practices, the groups did not differ with respect to smoking status, alcohol consumption, or physical activity. Although parents of cancer patients reported worse sleep hygiene than parents of healthy children, mediational analyses suggested that sleep was not responsible for stress-related reductions in immune system glucocorticoid sensitivity. Group differences also emerged in daily patterns of cortisol secretion. Parents of cancer patients had significantly flatter diurnal slopes than parents of medically healthy children, primarily because of a reduced output at 1 hr postawakening. Disparities in cortisol secretion patterns, however, could not explain the reduction in IL-6 glucocorticoid sensitivity among parents of cancer patients.

So, what mechanisms might be responsible for this effect? One possibility is that hormonal products of the SAM axis were oper-
ating as mediators. To the extent that chronic stress triggered the secretion of epinephrine and norepinephrine, these hormones could have downregulated glucocorticoid receptor expression and thereby contributed to the diminished glucocorticoid sensitivity of IL-6 (DeRijk et al., 1996; Maccari et al., 1992). Future studies might evaluate this hypothesis by collecting information regarding long-term epinephrine and norepinephrine output (Baum & Grunberg, 1995). It is also possible that cortisol was responsible for the reduced IL-6 glucocorticoid sensitivity among parents of cancer patients but did not emerge as a mediator in our study because of the timing of measurements. The HPA axis habituates to stressful experience fairly rapidly, and, in some cases, cortisol secretion rebounds to below normal levels (Frankenhauser, 1975; Heim, Ehlert, & Hellhammer, 2000; Lundberg, 1980). It is interesting to note that this pattern of blunted secretion emerged in an early study with parents of cancer patients (Friedman, Mason, & Hamburg, 1963), which found that cortisol levels were remarkably stable across time, even during periods when a child’s medical status had deteriorated significantly. Blunted cortisol secretion also has been described in patients who suffer from posttraumatic stress disorder (Yehuda, 1998, 2000; Yehuda et al., 1996), teachers with work-related burnout (Pruessner et al., 1999), women with conflicting role demands (Adam & Gunnar, 2001), breast cancer patients who experience accelerated mortality (Sephton, Sapolsky, Kraemer, & Spiegel, 2000), and soldiers in the midst of combat (Bourne, Rose, & Mason, 1967, 1968). Given that the average parent in our study had been dealing with cancer for more than 9 months at the time he or she participated, it is conceivable that declines in IL-6 glucocorticoid sensitivity arose from exposure to high concentrations of cortisol in the months shortly after diagnosis. With the passage of time, HPA axis function may have rebounded, while glucocorticoid receptor expression and/or function within white blood cells remained downregulated. To properly evaluate this hypothesis, of course, parents of cancer patients would need to be studied longitudinally from the time of diagnosis. Finally, it is possible that cortisol was responsible for chronic stress-related declines in IL-6 glucocorticoid sensitivity but did not emerge as a mediator because of the wide variability in secretion patterns across days. Future studies might overcome this reliability problem by boosting enrollment figures, collecting samples more frequently, and/or increasing the number of days of saliva collection (Stone et al., 2001).

We also hypothesized that social support would operate in a buffering fashion. Clear support emerged for this hypothesis, as support was unrelated to glucocorticoid sensitivity among parents of medically healthy children. Among parents of cancer patients, however, IL-6 glucocorticoid sensitivity declined to the extent that parents reported low tangible support. These findings suggest that the provision of material aid can offset the immunologic consequences of caring for a child with cancer, perhaps by ameliorating the substantial economic, occupational, and familial disruptions imposed by the disease and its treatment. Although it is not clear why, appraisal support does not appear to have the same impact on glucocorticoid sensitivity. Nevertheless, our findings corroborate evidence (Baron et al., 1990; Glaser et al., 1985, 1992; Kiecolt-Glaser et al., 1991; Kiecolt-Glaser, Garner, et al., 1984; Kiecolt-Glaser, Speicher, et al., 1984) suggesting that social support has the capacity to buffer people from the immunologic consequences of chronically stressful experience.

It is unclear why chronic stress did not also diminish dexamethasone’s capacity to suppress IL-1β and TNF-α. Glucocorticoids can block the production of all three cytokines we studied by

<table>
<thead>
<tr>
<th>Practice</th>
<th>Parents of children with cancer</th>
<th>Parents of medically healthy children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco and alcohol consumption</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% current smokers</td>
<td>20.0</td>
<td>12.0</td>
</tr>
<tr>
<td>% former smokers</td>
<td>8.0</td>
<td>8.0</td>
</tr>
<tr>
<td>Alcoholic drinks (per week)</td>
<td>2.3</td>
<td>1.9</td>
</tr>
<tr>
<td>Physical activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brisk activity (min/week)</td>
<td>46.0</td>
<td>80.2</td>
</tr>
<tr>
<td>Energy expenditure (Kcal/week)</td>
<td>875.1</td>
<td>1,193.9</td>
</tr>
<tr>
<td>Sleep hygiene</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjective sleep quality (1–4)</td>
<td>2.8</td>
<td>3.1</td>
</tr>
<tr>
<td>Sleep efficiency</td>
<td>0.8</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Note. n = 25 in each group. For each construct, means with different subscripts indicate group differences at p < .05 by independent samples t test.
inducing transcription of IxB. This molecule prevents NF-κB from translocating to the cell nucleus, where it activates the genes responsible for pro-inflammatory cytokine production (Scheinman, Cogswell, LoFquist, & Baldwin, 1995). Hence, there is no clear signaling-pathway explanation for the differential effects we observed. Other studies have found that short bouts of exercise and stress can reduce the glucocorticoid sensitivity of IL-1β and TNF-α (DeRijk et al., 1996, 1997; Rohleder et al., 2001; Smits et al., 1998). In fact, some evidence indicates that the sensitivity of these cytokines declines to a greater extent than IL-6 (DeRijk et al., 1997). Although the reason for these discrepancies is unclear, it seems likely that they are related to different neural and/or endocrine pathways being activated during acute versus chronic and psychological versus physiological forms of stress.

This study had a number of limitations. Perhaps the most important was its cross-sectional design, which precludes us from making any causal inferences regarding the relationship between chronic psychological stress and IL-6 glucocorticoid sensitivity. Although reverse causality is an unlikely explanation for our findings, it is conceivable that some unmeasured third variable was responsible, such as exposure to an environmental toxin that increases offspring cancer risk and disrupts immune function. Another important limitation of the study was that it relied on an assay system that does not closely resemble the in vivo environment in which white blood cells operate. Findings would have been more compelling if cortisol, rather than dexamethasone, had been used to suppress the production of cytokines. Although both of these agents have anti-inflammatoriy properties, dexamethasone is nearly 30 times more potent and primarily operates through a different isoform of the glucocorticoid receptor (Wilckens & DeRijk, 1997). Future studies may resolve this problem, and enhance their chances of detecting subtle alterations in glucocorticoid sensitivity, by using a cortisol-based assay system. Finally, it is not clear what implications our findings have for in vivo immune system glucocorticoid sensitivity. The stress-related declines in IL-6 sensitivity we observed were relatively small in magnitude, occurred in peripheral white blood cells stimulated in vitro, and did not extend to the other cytokines we assessed. These issues place important constraints on the generalizability of our findings to in vivo circumstances.

This study suggests that chronic psychological stress may reduce the immune system’s sensitivity to hormonal signals that normally terminate the inflammatory cascade. Before any definitive conclusions about this process can be reached, however, studies will need to replicate these findings and determine whether this represents a truly causal phenomenon. The latter could be accomplished through an experimental intervention trial aimed at increasing tangible support for parents of cancer patients (G. E. Miller & Cohen, 2001). It will also be important for future studies to delineate the mechanisms responsible for IL-6 glucocorticoid sensitivity, perhaps by longitudinally studying psychological, hormonal, and immune processes in parents of cancer patients from the time of their child’s initial diagnosis. A study of this nature would also enable investigators to explore the psychobiological consequences of dysregulated cytokine production. Given accumulating evidence that pro-inflammatory cytokines operate as stimulus for HPA activation (Maier & Watkins, 1998; A. H. Miller et al., 1999) and may contribute to depressive symptoms (Capuron, Ravaud, & Dantzer, 2000; Musselman et al., 2001), this could be a very fruitful line of research.

References
unemployment on salivary cortisol: Overall cortisol levels, diurnal rhythm, and acute stress reactivity. *Psychosomatic Medicine, 57*, 460–467.


